期刊文献+

结直肠癌患者MTHFR C677T基因多态性与基于氟尿嘧啶化疗方案疗效关系的系统评价 被引量:2

The correlation between the polymorphism of MTHFR C677T gene and the efficacy of fluorouracil-based chemotherapy in colorectal cancer patients: a systematic review
下载PDF
导出
摘要 目的系统性评价结直肠癌患者MTHFR C677T基因多态性与以氟尿嘧啶类药物为基础的化疗方案疗效之间的相关性。方法检索中国期刊网全文数据库(CNKI)、维普数据库、Pub Med、Embase和Web of Science数据库,时限为各数据库建库时间至2018年1月。2名研究者按照纳入与排除标准独立筛选文献、提取资料。采用Stata12. 0软件进行Meta分析,计算等位基因(T vs C)遗传模型下的效应量,以优势比(OR)及95%置信区间(CI)描述效应量,I2和Q检验评价异质性,采用逐一排除法进行敏感性分析,Begg检验和Egger检验评估发表偏倚。结果共纳入16项研究,共计1 521例患者。Meta分析结果显示,在等位基因模型中,MTHFR C677T基因多态性与氟尿嘧啶类药物化疗敏感性间无显著相关性(T vs C:OR=1. 05,95%CI=0. 80-1. 38)。按人种差异进行亚组分析也得到了同样的结果。敏感性分析显示研究结果较稳定,Begg和Egger检验结果表明纳入研究无明显发表偏倚。结论 MTHFR C677T基因多态性不是预测结直肠癌患者对含氟尿嘧啶类药物化疗方案敏感性的可靠指标。 Objective To systematically evaluate the correlation between MTHFR C677T polymorphism and the efficacy of fluorouracil chemotherapy in colorectal cancer patients. Methods Two researchers, by retrieving databases such as CNKI, VIP, PubMed, Embase and Web of Science (starting from the time of establishment of the database to January of 2018), screened relevant literature and information in accordance with the criteria for inclusion and exclusion. The obtained data were analyzed with Stata software (version 12) for Meta analysis and calculated the amount of effects under the genetic model of the allele (T vs C) and described with OR s and 95% CI. The heterogeneity is evaluated by 12 test and Q test. Sensitivity analysis using sequential exclusion method, and the publication bias was assessed by Begg's test and Egger's test. Results A total of 1521 patients were included in 16 studies. Meta analysis showed that there was no significant correlation between the polymorphism of MTHFR C677T gene and the sensitivity of fluorouracil chemotherapy in the allele model ( T vs C : OR = 1.05, 95% CI = 0.80 - 1.38). Subgroup analysis based on race differences gave the same results. Sensitivity analysis showed that the results of the study were relatively stable. Begg's test and Egger test showed that there was no significant publication bias in the study. Conclusion The polymorphism of MTHFR C677T gene can not be used as a reliable predictor of sensitivity of colorectal cancer patients to fluorouracil chemotherapy.
作者 钟磊 何霞 张远 串俊兰 彭倩 ZHONG Lei;HE Xia;ZHANG Yuan(Personalized Drug Therapy Key Laboratory of Sichuan Province,Hospital of the University of Electronic Science and Technology of China & Sichuan Provincial People's Hospital,Chengdu 610072,China)
出处 《临床合理用药杂志》 2018年第23期9-11,18,共4页 Chinese Journal of Clinical Rational Drug Use
关键词 结直肠癌 MTHFR 基因多态性 氟尿嘧啶 Colorectal cancer MTHFR Gene polymorphism Fluorouracil
  • 相关文献

参考文献3

二级参考文献32

  • 1刘德林,陆建伟,高长明,吴建中,尹必俭,周兆飞,Tajima Kazuo.MTHFR多态性对晚期胃癌患者化疗作用的预测研究[J].中华肿瘤防治杂志,2006,13(20):1564-1567. 被引量:8
  • 2JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J].CA Cancer J CUn, 201 1, 61(2):69-90.
  • 3TOURNIGAND C, ANDRE T, ACHILLE E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized CERCOR study[J].JClin Oncol, 2004, 22(2):229-237.
  • 4COLUCCI G, GEBBIA V, PAOLETTI G,et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Cruppo Oncologico Dell,Italia Meridionale[J].J Clin Oncol, 2005, 23(22):4866-4875.
  • 5DUCREUX M, BENNOUNA J, HEBBAR M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer[J]. Int J Cancer, 2011, 128(3):682-690.
  • 6ENCSTROM P F, ARNOLETTI J P,BENSON A R, et aL NCCN Clinical Practice Guidelines in Oncology: colon cancer[J]. J Natl Compr Cane Neter 2009, 7(8):778-831.
  • 7Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. AdvancedColorectal Cancer Meta-Analysis Project[J].J ClinOncol, 1992, 10(6):896-903.
  • 8VAN CUTSEM E, HOFF P M,HARPER P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials[J].BrJ Cancer, 2004, 90(6):11 90-1197.
  • 9HOFF P M,ANSARI R,BATIST G, ef al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study[J].J Clin Oncol, 2001,19(8):2282-2292.
  • 10DOROSHOW J H, MULTHAUF P, LEONG L,et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy[J]. J Clin Oncol, 1 990, 8(3):491-501.

共引文献17

同被引文献24

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部